Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Regen BioPharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and licensing of novel immunotherapy and regenerative medicine technologies. The company operates within the biopharmaceutical and life sciences industries, with an emphasis on oncology and immune-mediated diseases. Regen BioPharma does not currently commercialize approved drugs; instead, its business model centers on advancing early-stage therapeutic platforms and monetizing intellectual property through partnerships, licensing arrangements, or asset sales.
The company’s primary assets are internally developed and in-licensed therapeutic technologies, including engineered immune cell therapies, mRNA-based platforms, and antibody or peptide-based candidates. Regen BioPharma positions itself as an IP-focused biotech, seeking to create value through proprietary science rather than late-stage clinical commercialization. The company was founded in 2012 and has since evolved through multiple strategic shifts, including restructuring of its IP portfolio and renewed emphasis on oncology-focused immunotherapies. Public disclosures indicate ongoing efforts to strengthen patent positions and explore strategic transactions, though the ultimate commercial outcomes remain uncertain.
Business Operations
Regen BioPharma’s operations are organized around the research, development, and protection of its intellectual property portfolio rather than traditional product-based revenue streams. Its business activities include preclinical research oversight, patent prosecution, regulatory planning, and negotiation of potential licensing or collaboration agreements. The company has reported minimal recurring revenue, with funding historically derived from equity financing and, in limited cases, IP-related transactions.
The company’s technology portfolio has included platforms such as DuraCAR, a prolonged-expression CAR-T cell approach, mRNA-based immunotherapies, and t-cell vaccine technologies, though the development status of individual programs varies across disclosures. Regen BioPharma does not report significant international operations or manufacturing assets, and much of its research activity relies on external consultants, contract research organizations, and academic or commercial collaborators. Data inconclusive based on available public sources regarding the current clinical readiness of each platform.
Strategic Position & Investments
Strategically, Regen BioPharma seeks to position itself as a development-stage IP innovator capable of partnering with larger biotechnology or pharmaceutical companies. Its growth strategy emphasizes advancing preclinical data, strengthening patent estates, and pursuing licensing or joint development agreements rather than independently funding late-stage clinical trials. Public filings describe intentions to focus resources on oncology and immune-oncology assets perceived to have higher partnering potential.
The company has periodically announced acquisitions or in-licensing of intellectual property from third parties, though these transactions have generally been modest in scale and primarily involve patent rights rather than operating businesses. Regen BioPharma does not report ownership of revenue-generating subsidiaries or a diversified investment portfolio. Its strategic trajectory remains highly dependent on capital market access and successful validation of its technologies through preclinical or early clinical milestones.
Geographic Footprint
Regen BioPharma is headquartered in the United States, with its principal executive offices reported in California. The company’s operational footprint is largely domestic, with corporate governance, IP management, and strategic planning conducted from its U.S. base. It does not report dedicated international offices or laboratories.
Despite its limited physical presence, Regen BioPharma’s patent filings and scientific collaborations extend to multiple jurisdictions, reflecting the global nature of biopharmaceutical IP protection. The company has indicated interest in international licensing opportunities, but there is no verified evidence of sustained overseas operations or material revenue derived from non-U.S. markets.
Leadership & Governance
Regen BioPharma is led by executives with experience in biotechnology development, corporate finance, and IP-driven business models. Leadership communications emphasize capital efficiency, IP monetization, and long-term value creation through strategic partnerships rather than near-term product commercialization.
Key executives include:
- David Koos – Chief Executive Officer
- Paul B. Thompson – Chief Financial Officer
- Peter D. Suzdak – Chief Scientific Officer
The company is governed by a board of directors responsible for overseeing strategy, capital allocation, and compliance as a publicly traded entity on the OTC Markets. Governance disclosures indicate a small leadership structure consistent with early-stage biotechnology companies, with heavy reliance on external advisors and consultants.